Why Have Hormone Therapy Recommendations Changed?
Understanding the evolution of menopause medicine,
from the 2002 WHI study to today’s evidence-based care.
For many women, hormone replacement therapy (HRT) has long been surrounded by confusion and conflicting information. Much of that uncertainty can be traced back to the Women’s Health Initiative (WHI) study published in 2002.
The initial findings received widespread media attention and led millions of women to discontinue hormone therapy or avoid it altogether. However, researchers have spent more than two decades reexamining the data, and today’s scientific understanding is far more nuanced.
What We’ve Learned Since 2002
The original WHI study included many women who were significantly older than the average woman beginning menopause—most participants were in their 60s, and many started hormone therapy more than 10 years after menopause. Subsequent research has shown that age and timing matter significantly.
The “Window of Opportunity”
Current evidence indicates that healthy women who begin hormone therapy before age 60 or within 10 years of menopause often have a very different benefit-risk profile than women who start treatment later in life. This concept has become one of the most important advances in menopause medicine.
A New Era of Evidence-Based Care
Today’s recommendations emphasize personalized treatment rather than a one-size-fits-all approach.
In 2025, the U.S. Department of Health and Human Services (HHS) and the U.S. Food and Drug Administration (FDA) announced actions to update hormone therapy labeling and patient information to better reflect current scientific evidence. These updates recognize that earlier warnings did not adequately distinguish between women beginning therapy near menopause and those initiating treatment many years later.
Individualized Clinical Guidance
Current guidance encourages women and their healthcare providers to make customized decisions based upon: